ArticleLung India : official organ of Indian Chest Society2025
Exploring the possibility of a predictable precision therapy of COPD with inclusion of glycopyrronium responsiveness: A real-world experience.
Article in Lung India : official organ of Indian Chest Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The precision bronchodilator therapy in airflow limitation with asthma defining reversibility: An appraisal through pharmaco-responsiveness-based real-world observation.Lung India : official organ of Indian Chest Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe advent of glycopyrronium responsiveness has opened the prospect of selective responsiveness-based prescription of bronchodilators-β2-agonists or anti-muscarinic agents (AMA) for COPD. Such a concept needs ratification through clinical trials.
methodsStable COPD patients [post-bronchodilator FEV1/FVC <0.7] underwent serial glycopyrronium responsiveness [≥100 ml FEV1-improvement] after salbutamol before universal prescription of LABA-LAMA ± ICS as per guideline recommendation. At real-world follow-up, we noted the adverse and serious adverse events (exacerbations and hospitalizations) and, whenever possible, repeated spirometry in the similar fashion. Based on the initial glycopyrronium responsiveness, we divided the patients into glycopyrronium-sensitive and non-sensitive groups and compared the impact of treatment between them using spirometric variables (FEV1, FVC, FEV1/FVC and FEF25-75). We compared the 'trough'-FEV1 and 'total'-FEV1 (difference from the initial pre-bronchodilator to final post-dual-bronchodilator values) along with the frequency of exacerbation and hospitalization in each group.
resultsThe glycopyrronium-responsive and non-responsive groups (n = 30 for each) were similar demographically and on initial spirometry (pre-bronchodilator and post-salbutamol values). They received treatment for 162.4 ± 134.8 and 212 ± 118.1 days, respectively. The glycopyrronium-sensitive patients displayed significant improvement in both trough-FEV1 [0.17 ± 0.29 vs. 0.02 ± 0.2; (P = 0.0308)], total-FEV1 [0.32 ± 0.29 vs. 0.17 ± 0.21; (P = 0.0273) litres], in addition to trough FEF25-75 (P = 0.0204), total FEV1/FVC (0.0174) and total FEF25-75 (P = 0.0322). The exacerbations (P = 0.0056) were significantly lower in glycopyrronium-responsive patients.
conclusionThe glycopyrronium-responsive COPD patients show a significantly better overall improvement including the significant change in trough and total FEV1 with significantly reduced exacerbations in the real-world observation. The revelation demands more research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.